 | |
| Clinical data | |
|---|---|
| Other names | [(2R,3S,4S,5R)-3,4-dihydroxy-2,5,6-tris(methylsulfonyloxy)hexyl] methanesulfonate |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C10H22O14S4 |
| Molar mass | 494.51 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Mannosulfan (INN) is an alkylating agent with the potential for the treatment of cancer. It is not approved by the United States FDA for cancer treatment. Research suggests it is less toxic than the alkyl sulfonate Busulfan.[1]
References
edit- ^ Jeswani G, Paul SD (2017). "Recent Advances in the Delivery of Chemotherapeutic Agents". Nano- and Microscale Drug Delivery Systems. pp. 281–98. doi:10.1016/B978-0-323-52727-9.00015-7. ISBN 978-0-323-52727-9.
External links
edit
Media related to Mannosulfan at Wikimedia Commons
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information. |
